ZA953703B - Modified live BRSV vaccine - Google Patents

Modified live BRSV vaccine

Info

Publication number
ZA953703B
ZA953703B ZA953703A ZA953703A ZA953703B ZA 953703 B ZA953703 B ZA 953703B ZA 953703 A ZA953703 A ZA 953703A ZA 953703 A ZA953703 A ZA 953703A ZA 953703 B ZA953703 B ZA 953703B
Authority
ZA
South Africa
Prior art keywords
immunity
adjuvant
brsv
modified live
polyoxypropylene
Prior art date
Application number
ZA953703A
Other languages
English (en)
Inventor
Hsien-Jue Chu
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of ZA953703B publication Critical patent/ZA953703B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA953703A 1994-05-10 1995-05-08 Modified live BRSV vaccine ZA953703B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24037394A 1994-05-10 1994-05-10

Publications (1)

Publication Number Publication Date
ZA953703B true ZA953703B (en) 1996-01-10

Family

ID=22906268

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953703A ZA953703B (en) 1994-05-10 1995-05-08 Modified live BRSV vaccine

Country Status (20)

Country Link
US (2) US5733555A (zh)
EP (4) EP0968722B1 (zh)
JP (3) JP3993230B2 (zh)
KR (1) KR100374434B1 (zh)
CN (1) CN1268393C (zh)
AT (2) ATE365049T1 (zh)
AU (1) AU711350B2 (zh)
BR (1) BR9507717A (zh)
CA (1) CA2189979C (zh)
DE (2) DE69518316T2 (zh)
DK (2) DK0759780T3 (zh)
ES (3) ES2429401T3 (zh)
GR (1) GR3034402T3 (zh)
HK (1) HK1024412A1 (zh)
MY (1) MY111829A (zh)
NZ (1) NZ285324A (zh)
PT (3) PT1820512E (zh)
SI (2) SI0759780T1 (zh)
WO (1) WO1995030437A1 (zh)
ZA (1) ZA953703B (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
CA2145418A1 (en) * 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
BR9507023A (pt) * 1994-03-07 1997-09-23 Inhale Therapeutic Syst Processos para aerossolização de uma dose de insulina para a liberação respiratória de insulina e para preparação de uma composição de insulina e composição de insulina
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
CN1073119C (zh) * 1994-05-18 2001-10-17 吸入治疗系统公司 干扰素干粉配方的方法及组合物
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
PT784486E (pt) * 1994-10-05 2006-07-31 Univ Vanderbilt Inerleucina-12 como um adjuvante para vacinas contra paramyxoviridae
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
TW440845B (en) 1999-08-11 2001-06-16 Ibm Method and system for programming FPGAs on PC-cards without additional hardware
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MXPA03010208A (es) 2001-05-10 2004-03-10 Wyeth Corp Composicion y metodo para incrementar densidad celular en cultivos celulares infectados con lentivirus.
MXPA03011599A (es) 2001-07-02 2005-03-07 Pfizer Prod Inc Vacunacion en dosis unica con micoplasma hyopneumoniae.
KR20090053967A (ko) * 2001-07-27 2009-05-28 와이어쓰 웨스트 나일 백신
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
EA011578B1 (ru) * 2002-08-26 2009-04-28 Пфайзер Продактс Инк. Иммуногенная композиция для защиты крупного рогатого скота от инфекций респираторной и репродуктивной систем и ее применение
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8097288B1 (en) * 2008-04-16 2012-01-17 Pom Wonderful, Llc Composition and method for providing nutritional immunology for production animals
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
TW200744640A (en) * 2005-08-04 2007-12-16 Wyeth Corp Stabilizers for veterinary vaccines
PL3127551T3 (pl) 2005-12-29 2020-12-28 Boehringer Ingelheim Animal Health USA Inc. Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
US20100129397A1 (en) * 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CA2670836C (en) 2006-12-15 2018-09-04 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
BRPI0907438A2 (pt) * 2008-01-23 2015-08-04 Boehringer Ingelheim Vetmed Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
AR084358A1 (es) 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
ES2709190T3 (es) * 2010-12-27 2019-04-15 Elanco Us Inc Composiciones de vacuna contra el virus de la diarrea viral bovina tipo 1B y procedimientos
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
DK2994162T3 (en) 2013-05-08 2021-06-21 Pharmgate Biologics Inc Vaccine for pcv2 og mycoplasma
MX2016003855A (es) 2013-09-25 2016-08-04 Zoetis Services Llc Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
CA2924228C (en) 2013-10-02 2024-01-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
US20210290754A1 (en) * 2018-08-07 2021-09-23 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP2022522112A (ja) 2019-02-08 2022-04-14 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
MX2022005919A (es) * 2019-11-18 2022-06-22 Elanco Us Inc Masa liofilizada en vial de pared recta.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine

Also Published As

Publication number Publication date
EP0968722B1 (en) 2007-06-20
EP0759780A1 (en) 1997-03-05
CN1152878A (zh) 1997-06-25
JP3993230B2 (ja) 2007-10-17
JPH10500113A (ja) 1998-01-06
SI0759780T1 (en) 2000-12-31
AU711350B2 (en) 1999-10-14
EP1844791A1 (en) 2007-10-17
CN1268393C (zh) 2006-08-09
AU2438795A (en) 1995-11-29
PT968722E (pt) 2007-09-06
GR3034402T3 (en) 2000-12-29
EP1820512B1 (en) 2013-07-03
CA2189979C (en) 2011-04-19
SI0968722T1 (sl) 2007-10-31
ES2287997T3 (es) 2007-12-16
ES2429401T3 (es) 2013-11-14
KR100374434B1 (ko) 2003-06-09
DK0968722T3 (da) 2007-09-24
MY111829A (en) 2001-01-31
HK1024412A1 (en) 2000-10-13
DK0759780T3 (da) 2000-11-13
KR970703166A (ko) 1997-07-03
ES2149361T3 (es) 2000-11-01
US5958423A (en) 1999-09-28
ATE365049T1 (de) 2007-07-15
ATE195255T1 (de) 2000-08-15
PT1820512E (pt) 2013-10-09
DE69535520D1 (de) 2007-08-02
US5733555A (en) 1998-03-31
WO1995030437A1 (en) 1995-11-16
EP1820512A1 (en) 2007-08-22
JP2011246489A (ja) 2011-12-08
PT759780E (pt) 2001-01-31
DE69535520T2 (de) 2008-02-07
NZ285324A (en) 1998-08-26
BR9507717A (pt) 1997-09-23
JP2007137905A (ja) 2007-06-07
CA2189979A1 (en) 1995-11-16
DE69518316T2 (de) 2001-03-29
EP0968722A1 (en) 2000-01-05
DE69518316D1 (de) 2000-09-14
EP0759780B1 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
GR3034402T3 (en) Improved modified live brsv vaccine
WO2004058142A3 (en) Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses
MY129765A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
AUPP807399A0 (en) Improved immunogenic lhrh composition and methods relating thereto
CA2258878A1 (en) Liposomal influenza vaccine composition and method
CA2201598A1 (en) Vaccine compositions
ZA97452B (en) Streptococcus equi vaccine.
AU4622693A (en) Potentiation of immunogenic response
CA2139507A1 (en) Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants
HUP0100058A1 (hu) LTB Adjuvánst tartalmazó vakcinák
WO1999040938A3 (en) Vaccines comprising interleukin-12 and herpes simplex viral antigen
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
CA2182274A1 (en) Antigenic preparation for treatment or prevention of helicobacter infection
EP1666057A3 (en) An acellular vaccine comprising Bordetella pertussis antigens
WO1997045139A3 (en) Il-12 as an adjuvant for bordetella pertussis vaccines
FI952445A0 (fi) Pneumokokiantigeenien annostelu limakalvojen kautta
MX9605503A (es) Vacuna mejorada de virus sincitial respiratorio debovino (brsv) vivo, modificado.
Chu Modified live BRSV vaccine
CA2137363A1 (en) Use of Zona Pellucida Glycoproteins for Immunocontraception
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
AU8144194A (en) Vaccine against mumps containing a jeryl-lynn virus strain
CA2128247A1 (en) Vaccines based on streptokinase